[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

New Medicine, Pharmaceuticals & Biotechnology Markets Reports Published at MarketPublishers.com

06 Jan 2012 • by Natalie Aster

LONDON - Market Publishers Ltd informs that new in-demand GBI Research reports on medicine, pharmaceuticals & biotechnology markets have been added to its catalogue.

Emerging Market for Clinical Trials in Poland - Cost Advantages of Nearly 30% as Compared to the US. With the speed of patient recruitment and quality of clinical trial data, Poland is becoming an attractive location for conducting clinical research. Moreover, improvements in clinical trial regulation could drive the market in the upcoming years. The report provides key data, information and analysis of the major trends and issues affecting the clinical trial market in Poland ...

Endpoints - Clinical Trials in Dermatology - Inflammatory Lesions Count is the Key Determinant of Success in Acne Vulgaris Clinical Trials. The study examines different aspects under clinical trial endpoints in dermatology including analysis on major marketed drugs, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising drugs with more emphasis on safety, efficacy and clinical trial details, and terminated trial analysis. The profiles of the top companies are also included ...

Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma. Most of the orphan diseases (80%) are often genetic, while the remaining diseases occur due to allergies, degenerative and proliferative causes and as a result of infection. The report provides true insights into different endpoints that are used in orphan disease clinical trials. It highlights the seven major orphan diseases, presents analysis of the Phase III and Phase II clinical trials in terms of percentage of cases, and more ...

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma. The global hospital acquired bacterial infections (HABI) market is forecast to decline at a negative CAGR of 3.4% over the review period. This is due to the resistance developed against antibacterials as well as an increase in hospital surveillance. In-depth analysis of drivers and barriers that impact the global hospital acquired bacterial infections market and more can be found in the report ...

More new market research reports by the publisher can be found at GBI Research page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest